The Patent and Trademark Office has granted...

The Patent and Trademark Office has granted a patent to Cetus Corp. covering PEG interleukin-2, an advanced form of the company’s investigational anti-cancer agent, interleukin-2 (IL-2). Cetus initiated human clinical testing of PEG IL-2 in April of this year. Cetus now holds more than a dozen U.S. patents on various forms of interleukin-2 and processes for its manufacture. This new patent complements an exclusive worldwide license held by Cetus under a broad patent generally covering PEG proteins owned by Research Corporation Technologies Inc. This license agreement covers use of the PEG technology as it pertains to IL-2.